Edition:
Deutschland

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

3,904JPY
04:41 Uhr
Change (% chg)

¥29 (+0.75%)
Prev Close
¥3,875
Open
¥3,861
Day's High
¥3,925
Day's Low
¥3,842
Volume
939,800
Avg. Vol
2,603,215
52-wk High
¥4,241
52-wk Low
¥2,284

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Buy/Sell

Sell Hold Buy
2.67 Mean rating from 12 analysts

Overall

Beta: 0.84
Market Cap(Mil.): ¥1,772,528.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.80

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

BRIEF-R&I affirms Daiichi Sankyo's rating at "AA" and says negative outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

BRIEF-Daiichi Sankyo to merge with unit Asubio Pharma

* Says it will merge with wholly owned unit Asubio Pharma Co., Ltd., effective April 1, 2018

BRIEF- Daiichi Sankyo to repurchase shares for up to 50 bln yen

* Says it plans to buy back up to 28 million shares, representing 4.2 percent of outstanding, for up to 50 billion yen, during period from Nov. 1 to March 23, 2018

BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock

* Says it will buy back up to 50 billion yen ($442 million) of stock through March 23 Further company coverage: ($1 = 113.1500 yen) (Reporting By Chris Gallagher)

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage:

BRIEF-Inovalon enters into agreement with Daiichi Sankyo Inc

* Inovalon announces agreement with daiichi sankyo, inc. To support outcomes-based contracting

Deals of the day-Mergers and acquisitions

Aug 31 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

Photo

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca , following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.24%
Rohstoffe -0.32%
Industrie -0.21%
Konjunktur abhängige Waren & Dienstleistungen -0.18%
Konjunktur unabhängige Waren & Dienstleistungen -0.16%
Finanzindustrie -0.08%
Pharma -0.07%
Technologie -0.20%
Telekommunikation -0.05%